Literature DB >> 17052732

Treatment of Susac syndrome with gamma globulin and corticosteroids.

Robert J Fox1, Fiona Costello, Alexander R Judkins, Steven L Galetta, Albert M Maguire, Brian Leonard, Clyde E Markowitz.   

Abstract

Susac syndrome is a rare vasculopathy characterized by visual, hearing, and cognitive dysfunction. Optimal treatment is unknown, but many patients require chemotherapy to control disease activity. We describe two patients with Susac syndrome and their response to intravenous immune globulin (IVIg) and corticosteroids. Both patients improved following acute treatment with IVIg and intravenous methylprednisolone (IVMP), and no further relapses were observed. One patient showed significant improvement in hearing and MRI lesions shortly following acute treatment. Treatment with IVIg and corticosteroids provides a therapeutic option that avoids the toxicities of chemotherapy and suggests the possible importance of pathologic antibodies in the pathogenesis of Susac syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052732     DOI: 10.1016/j.jns.2006.08.007

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  16 in total

Review 1.  [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

2.  Treatment of Susac Syndrome.

Authors:  Ivana Vodopivec; Sashank Prasad
Journal:  Curr Treat Options Neurol       Date:  2016-01       Impact factor: 3.598

3.  The spectrum of Susac's syndrome.

Authors:  Siddharama Pawate; Anita Agarwal; Harold Moses; Subramaniam Sriram
Journal:  Neurol Sci       Date:  2009-01-15       Impact factor: 3.307

Review 4.  [Susac syndrome: an interdisciplinary challenge].

Authors:  J Dörr; S Jarius; B Wildemann; E B Ringelstein; W Schwindt; M Deppe; K P Wandinger; J Promesberger; F Paul; I Kleffner
Journal:  Nervenarzt       Date:  2011-10       Impact factor: 1.214

Review 5.  Distinguishing Susac's syndrome from multiple sclerosis.

Authors:  Katherine A Buzzard; Stephen W Reddel; Con Yiannikas; D Sean Riminton; Michael H Barnett; Todd A Hardy
Journal:  J Neurol       Date:  2014-12-30       Impact factor: 4.849

Review 6.  Characteristics of Susac syndrome: a review of all reported cases.

Authors:  Jan Dörr; Sarah Krautwald; Brigitte Wildemann; Sven Jarius; Marius Ringelstein; Thomas Duning; Orhan Aktas; Erich Bernd Ringelstein; Friedemann Paul; Ilka Kleffner
Journal:  Nat Rev Neurol       Date:  2013-04-30       Impact factor: 42.937

7.  Clinical outcomes of intravenous immunoglobulin therapy in refractory uveitis.

Authors:  M Garcia-Geremias; E Carreño; S J Epps; R W J Lee; A D Dick
Journal:  Int Ophthalmol       Date:  2015-02-24       Impact factor: 2.031

Review 8.  Autoimmune vertigo: an update on vestibular disorders associated with autoimmune mechanisms.

Authors:  Francesca Yoshie Russo; Massimo Ralli; Daniele De Seta; Patrizia Mancini; Alessandro Lambiase; Marco Artico; Marco de Vincentiis; Antonio Greco
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

9.  Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome.

Authors:  Jan Dörr; Helena Radbruch; Markus Bock; Jens Wuerfel; Anne Brüggemann; Klaus P Wandinger; Daniel Zeise; Caspar F Pfueller; Frauke Zipp; Friedemann Paul
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

10.  [Aggressive immunotherapy in Susac's syndrome].

Authors:  M Klein; T Illies; S Georgi; T Rosenkranz; C Terborg
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.